it is a concern that AHZ has risen so quickly, I'm still of the view that fundamentals have to catch up with the increase in market cap (now $120m - that's a serious figure for a small biotech no matter what 'potential' it has). Seems like many posters simply assume the Herpes vaccine is in the bag - it isn't, it has many years of Phase III trials to get to that point and Herpes vaccines have been a graveyard for other bio's. Still you can't say AHZ will never achieve its goal but there's a lot of hard yards yet....
looking at the chart, that's one precipitous sp increase, not many companies have managed to sustain 'chimney stack' chart configurations. Again, AHZ might be an exception, but that remains to be seen. I follow what the market says and although when AHZ was at 3c I was not a fan of AHZ (though I don't believe as one poster misleadingly said that I ever called it a dog stock) I have nevertheless been forced to pay homage to the market and have steadily bought since 4.5c so to those who stupidly think I've missed out, sorry to disappoint you.....
where to from here? in my view a continuance of recent gains will at some point attract a correction - that's how stuffs works. You might choose to believe AHZ is an exception - that's your business. I'll remain a holder until I see signs of exhaustion, but IMO a run up on hype to some level such as 20c which makes a MC of $200m is not in AHZ's best interests. Very long term, IF AHZ achieves all its goals then the sp has the potential to increase significantly more, who would argue with that? but isn't that the case for every stock on the ASX?
so far so good....
AHZ Price at posting:
10.8¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)